17 completed, 5 unknown, 2 terminated. 7 Not applicable, 7 Phase 3, 6 Phase 2, 2 Phase 1, 2 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Not applicable | 7 | Completed 4, Unknown 2, Terminated 1 |
| Phase 3 | 7 | Completed 4, Unknown 2, Terminated 1 |
| Phase 2 | 6 | Completed 6 |
| Phase 1 | 2 | Completed 2 |
| Phase 4 | 2 | Completed 1, Unknown 1 |
Follow House Dust Mite Allergy: new trials by email Literature Review of House Dust Mite Allergy trials Research Report on House Dust Mite Allergy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| BÜHLMANN BAT (Basophil Activation Test) in Allergy Diagnosis (Exploratory Pilot Study) Allergy Testing, Peanut Allergies | Completed | Bühlmann Laboratories AG | 38 | 2026-05-15 | 2026-07-17 | |
| Evaluation of an Adjusted Cutoff Value for S.P.A.T (Skin Prick Automated Test) Device in Allergic Subjects Skin Prick Automated Test, Skin Prick Manual Test, Nasal Allergen Challenge - House Dust Mite Allergy, Birch Pollen Allergy | Not applicable | Completed | Hippocreates | 75 | 2024-09-17 | 2025-01-31 |
| A Randomized, Double-Blind, Placebo-Controlled, Multi-Centre Study to Assess the Efficacy of PURETHAL Mites Mixture 50,000 AUeq/mL Subcutaneous Immunotherapy in Adult Subjects With Moderate to Severe Allergic Rhinitis/Rhinoconjunctivitis With or Without Asthma Induced by House Dust Mite (HDM) PURETHAL Mites 50,000 AUeq/ml, Biological/Vaccine: Placebo - House Dust Mite Allergy, House Dust Mite Rhinitis | Phase 3 | Completed | HAL Allergy | 691 | 2024-09-09 | 2026-08-10 |
| Efficacy and Safety Evaluation for the Treatment of HDM Induced Allergic Asthma and Rhinitis/Rhinoconjunctivitis MM09 allergoid-mannan conjugates subcutaneous (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (3.000 UTm/mL), MM09 allergoid-mannan conjugates Sublingual (9.000 UTm/mL) - House Dust Mite Allergy, Perennial Allergic Rhinitis | Phase 3 | Unknown | Inmunotek S.L. | 400 | 2022-12-01 | 2022-11-18 |
| The Efficacy of Nigella Sativa in Children With House Dust Mite-Induced Respiratory Allergy Receiving Immunotherapy Nigella Sativa Oil, Allergen Specific Immunotherapy, Standard pharmacotherapy - House Dust Mite Allergy | Not applicable | Unknown | Universitas Airlangga | 40 | 2022-08-01 | 2022-07-08 |
| Efficacy and Safety Assessment of Beltavac® With Polymerized Extract of HDM House dust mites allergoid from Dermatophagoides pteronyssinus and Dermatophagoides farinae, Placebo - House Dust Mite Allergy | Phase 3 | Unknown | Probelte Pharma S.L.U. | 350 | 2022-01-17 | 2024-07-18 |
| Skin Responses and T Cell Immunology After House Dust Mite Exposure in Sensitized Atopic Dermatitis Patients House Dust Mite Allergen, Allergen-free air - Atopic Dermatitis, House Dust Mite Allergy | Not applicable | Completed | Fraunhofer-Institute of Toxicology and Experimental Medicine | 23 | 2021-09-10 | 2024-10-15 |
| Epigenetic Regulation of Exercise Induced Asthma Exercise challenge in the cold chamber (ECC), mRNA profile, standard diagnostic - Exercise Induced Asthma, House Dust Mite Allergy | Not applicable | Unknown | Johann Wolfgang Goethe University Hospital | 68 | 2021-08-01 | 2022-01-03 |
| Efficacy and Safety Evaluation for the Treatment of Asthma and Allergic Rhinitis/Rhinoconjunctivitis MM09-MG01(30.000-30.000), MG01(30.000), MM09(30.000) - Allergic Rhinoconjunctivitis, Perennial Allergic Rhinitis | Phase 3 | Terminated | Inmunotek S.L. | 18 | 2021-04-30 | 2023-12-19 |
| Diagnostic Accuracy of the MADx Multi Array Xplorer (MAX 45k) Automated Laboratory System and the MADx Allergy Explorer Version 2 (ALEX²) - IgE Multiplex Test for the Diagnosis of Pre-defined Groups of Specific High-priority Allergens ALEX² test using the MAX 45k automated laboratory system - Birch Pollen Allergy, Grass Pollen Allergy | Not applicable | Completed | MacroArray Diagnostics GmbH | 839 | 2020-07-22 | 2022-04-22 |
| Safety and Clinical Tolerability of hdmASIT+TM Peptides Administered in HDM-induced Allergic Patients Placebo solution, hdmASIT+TM - House Dust Mite Allergy | Phase 2 | Completed | ASIT Biotech S.A. | 36 | 2016-09-28 | 2017-03-29 |
| Efficacy & Safety of STG320 Sublingual Tablets of HDM Allergen Extracts in Adults and Adolescents With HDM-associated AR 300 IR, Placebo - Rhinitis, Allergic, Perennial, House Dust Mite Allergy | Phase 3 | Completed | Stallergenes Greer | 1607 | 2015-09-29 | 2019-10-14 |
| SUBLIVAC FIX Mite Mixture Dose Tolerability Study SUBLIVAC FIX Mite mixture, Placebo - House Dust Mite Allergy | Phase 1 / Phase 2 | Completed | HAL Allergy | 81 | 2015-05-01 | 2015-12-02 |
| AZELASTINE/FLUTICASONE (AZE/FLU) Nasal Spray on Symptom Control, Nasal Mediators and Nasal Hyperresponsiveness in Allergic Rhinitis (AR) azelastine + fluticasone, Placebo - Allergic Rhinitis, House Dust Mite Allergy | Phase 4 | Unknown | Universitaire Ziekenhuizen KU Leuven | 45 | 2014-10-01 | 2015-12-03 |
| Dose Ranging Study of SLIT Tablets of House Dust Mite Allergen Extracts (HDM) in Adults With HDM-associated Allergic Asthma SLIT tablets of HDM allergen extracts, 3 different doses (A), SLIT tablets of HDM allergen extracts, 3 different doses (B), SLIT tablets of HDM allergen extracts, 3 different doses (C) - Asthma, House Dust Mite Allergy | Phase 2 | Completed | Stallergenes Greer | 386 | 2013-09-01 | 2015-12-18 |
| ToleroMune House Dust Mite Follow on Study House Dust Mite Allergy, Rhinoconjunctivitis | Completed | Circassia Limited | 105 | 2013-09-01 | 2014-05-15 | |
| Role of the Central Nervous System in Allergic Rhinitis histamine, sham - House Dust Mite Allergy | Not applicable | Terminated | Universitaire Ziekenhuizen KU Leuven | 14 | 2012-11-01 | 2015-12-03 |
| Safety Study of Sublingual Immunotherapy Tablets of House Dust Mite Allergen Extracts SLIT tablets of house dust mite allergen extracts, Matching placebo - Asthma, House Dust Mite Allergy | Phase 1 | Completed | Stallergenes Greer | 94 | 2012-05-01 | 2014-07-01 |
| A One Year Trial Evaluating the Safety and Efficacy of the ALK House Dust Mite Allergy Tablet AIT Tablet - House Dust Mite Allergy | Phase 3 | Completed | ALK-Abelló A/S | 992 | 2011-10-01 | 2017-01-30 |
| Safety of Bronchial Allergen Challenge and Predictors for Positive Reaction. house dust mite and alternaria allergen bronchial challenge - House Dust Mite Allergy, Bronchial Hyperresponsiveness | Not applicable | Completed | Johann Wolfgang Goethe University Hospital | 425 | 2011-01-01 | 2023-03-13 |
Showing 20 of 24. Sign in to see all of them.
Dust Mite Allergy (24) · Hypersensitivity (4) · Rhinitis, Allergic, Perennial (3) · Asthma (2) · Rhinitis, Allergic (2) · Venom Hypersensitivity (2) · Asthma, Exercise-Induced (1) · Bronchial Hyperreactivity (1) · Dermatitis, Atopic (1) · Peanut Hypersensitivity (1) · Rhinitis (1) · Rhinitis, Allergic, Seasonal (1)
Hypersensitivity, Immediate (24) · Immune System Diseases (24) · Nose Diseases (24) · Otorhinolaryngologic Diseases (24) · Respiratory Hypersensitivity (24) · Respiratory Tract Diseases (24) · Rhinitis (23) · Rhinitis, Allergic (22) · Rhinitis, Allergic, Perennial (21) · Hypersensitivity (20) · Bronchial Diseases (4) · Lung Diseases (2) · Lung Diseases, Obstructive (2) · Asthma (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1)
Antigens, Dermatophagoides (5) · CYT003-QbG10 (2) · Biological Products (1) · Fish Oils (1) · Fluticasone (1) · Histamine (1) · Nigella sativa oil (1) · Sublingual Immunotherapy (1) · azelastine (1) · salicylhydroxamic acid (1)
Johann Wolfgang Goethe University Hospital (3) · Stallergenes Greer (3) · Cytos Biotechnology AG (2) · HAL Allergy (2) · Inmunotek S.L. (2) · Universitaire Ziekenhuizen KU Leuven (2) · ALK-Abelló A/S (1) · ASIT Biotech S.A. (1) · Allergopharma GmbH & Co. KG (1) · Bühlmann Laboratories AG (1) · Circassia Limited (1) · Fraunhofer-Institute of Toxicology and Experimental Medicine (1) · Hippocreates (1) · MacroArray Diagnostics GmbH (1) · Probelte Pharma S.L.U. (1)
Germany (9) · France (5) · Spain (3) · Belgium (2) · Poland (2) · Austria (1) · Bulgaria (1) · Latvia (1) · Lithuania (1) · Switzerland (1) · United States (1)
Pascal Demoly, MD (3) · Philipp Mueller, MD (2) · Alina Gherasim, MD (1) · Ana Isabel Tabar Purroy, MD. PhD (1) · Ana Isabel Tabar Purroy, MD; PhD (1) · Annemie Narkus, M.D. (1) · Hans Hoogeveen (1) · Ida Bagus Ramajaya Sutawan, MD (1) · Jens M Hohlfeld, Prof. Dr. (1) · Johannes Schulze, Dr. (1) · Margitta Worm, Prof.Dr.med. (1) · Peter Hellings, Dr (1) · Prof. Stefan Zielen, M.D. (1) · Tom Casale, MD (1)
PMID 23331526, PMID 29656145, PMID 38225952, PMID 39035788
2016 (1), 2018 (1), 2023 (1)